Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion ...
The convergence of two already fantastic industries is creating an incredible opportunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results